Skip to main content

Table 1 Frequency of alterations of TP53, MDM2, and MDMX in relevant hematological neoplasia diseases

From: MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

Disease

TP53 mutations

TP53 17p deletion

MDM2 overexpression/trisomy 12

MDMX overexpression

References

ALL

13.5 ± 0.7 (459 pt)

4.3 ± 1.2 (1731 pt)

29.3 ± 4.7 (101 pt)

80 (55 pt)

[147,148,149,150]

AML

13.5 ± 2.7 (2934 pt)

1.5 ± 0.7 (2398 pt)

49 (189 pt)

10.7 (140 pt)

[150,151,152,153,154,155,156]

BL

17.3 ± 9 (218 pt)

10 (28 pt)

13.5 ± 13.4 (109 pt)

21 (30 pt)

[157,158,159]

CLL

10.2 ± 1.5 (3703 pt)

6.8 ± 1.9 (3523 pt)

13.8 ± 1.8 (3523 pt)

21 (131 pt)

[76, 150, 160,161,162,163,164]

MM

8.2 ± 5.2 (733 pt)

10.2 ± 2.7 (954 pt)

8 (82 pt)

na

[165,166,167,168,169,170]

NHL

24.4 ± 6.4 (1337 pt)

25 ± 7.1 (75 pt)

15.1 ± 17.2 (851 pt)

na

[171,172,173,174,175,176,177]

WM/LPL

7 (30 pt)

8.7 ± 1 (206 pt)

4 ± 1.4 (214 pt)

na

[178,179,180,181,182]

  1. The percentages of abnormalities were calculated after compiling cases reported in literature (total number of patients is indicated in bracket) and are reported as mean ± standard deviation
  2. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BL Burkitt lymphoma, CLL chronic lymphocytic leukemia, MM multiple myeloma, NHL non-Hodgkin lymphoma, WM/LPL Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, na not available